# Barosense

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/barosense

- Industry: Medical Devices & Equipment
- Headquarters: Redwood City, US
- Website: www.barosense.com
- Total disclosed funding: $51M
- Latest round: Series B (Nov 30, 2009)
- Investors on record: 8

## About

Barosense specializes in the sale of premium web domains, providing a streamlined platform for businesses and individuals to purchase and finance unique domain names essential for online branding.Barosense was founded in 2001 in Redwood City, US, and operates as an independent entity. The company primarily focuses on domain name sales, allowing users to acquire domains either outright or through flexible payment plans. The founder, Bill Starling, has a history of entrepreneurship, although no details about previous companies are provided. The latest funding round was a Series D, where Barosense raised USD 27.49 mn in total, with a current valuation of USD 111.298 mn. In July 2013, Boston Scientific acquired Barosense for an undisclosed amount.Barosense.com specializes in domain name sales, offering a streamlined platform for purchasing premium web domains such as Barosense.com itself. The core product of the company is the sale of domain names, vital for establishing an online presence. Customers can buy domains outright or utilize flexible financing options. The primary end users include entrepreneurs, startups, and established companies looking to secure unique domain names that align with their brand identities. Barosense.com operates primarily within the United States, with its services accessible globally.Barosense's revenue model is structured around direct sales of domain names, with a pricing strategy that includes a fixed purchase price or monthly payment plans. Customers can acquire domains for a one-time fee, such as Barosense.com priced at USD 4,795, or can finance it at USD 399.58 per month. The transaction process is efficient, with customers gaining access to their purchased domains shortly after payment completion. The firm enhances customer satisfaction through a 30-day money-back guarantee, supporting its revenue generation efforts.Looking ahead, Barosense aims to enhance its product offerings with new domain name options and improved financing plans. The company is exploring expansion into international markets, specifically targeting European and Asian regions by 2025, to broaden its customer base. Recent funding from the Series D round will support these initiatives, allowing Barosense to invest in technology and marketing to reach a wider audience.

## Funding rounds

- Series B, Nov 30, 2009 — Inovia Capital
- Series D, Sep 24, 2009, $27M — Delphi Ventures, Frazier Healthcare Partners, Invesco, Pappas Capital, RWI Ventures, Synergy Life Science Partners, Wharton Asset Management
- Series C, Dec 21, 2006, $7M — Frazier Healthcare Partners, Invesco
- Series B, Dec 8, 2004, $10M — Delphi Ventures, Frazier Healthcare Partners, Invesco, RWI Ventures
- Series A, Sep 20, 2002, $6.2M — Delphi Ventures, Frazier Healthcare Partners

## Investors

- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series A, Series B, Series D
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series B, Series C, Series D
- Invesco (https://capitalatlas.ai/funds/invesco) — Series B, Series C, Series D
- RWI Ventures (https://capitalatlas.ai/funds/rwi-ventures) — Series B, Series D
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series D
- Synergy Life Science Partners (https://capitalatlas.ai/funds/synergy-life-science-partners) — Series D
- Wharton Asset Management — Series D
- Inovia Capital (https://capitalatlas.ai/funds/inovia-capital) — Series B